Insulin Glulisine (Apidra)
Insulin glulisine (Apidra) is a rapid-acting insulin analogue with two amino-acid substitutions (B3 lysine, B29 glutamate). It behaves much like lispro and aspart and is used off-label the same way for post-workout glucose disposal. It carries identical life-threatening hypoglycaemia risk.
01 Overview
Glulisine's substitutions promote a monomeric state without needing zinc, giving rapid subcutaneous absorption. It is an approved mealtime insulin with a solid clinical evidence base in diabetes.
Bodybuilders treat it as another fast analogue for nutrient timing around carbohydrate and training. It offers no meaningful safety advantage for non-diabetic use, and the same rapid hypoglycaemia hazard applies.
02 Mechanism
Stimulates the insulin receptor to increase GLUT4-mediated glucose uptake, glycogen and protein synthesis, and to suppress lipolysis and hepatic glucose output; formulation favours rapid monomeric absorption.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Beginner (off-label) | 1–5 IU | SubQ | Paired with carbohydrate; extreme caution |
| Diabetic bolus | 4–20 IU | SubQ | Individualised; medical use only |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Glycogen loadingRapid glucose disposal into muscle with carbohydrate feeding. | Increased muscle fullness | Clinical | |
| Anabolic signallingSupports protein synthesis and reduces catabolism via insulin-receptor pathways. | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Fat accumulationFat gain in a caloric surplus. | Mild | Common | Clinical | |
| Severe hypoglycaemiaRapid, dangerous fall in blood glucose with neuroglycopenia, seizure and coma. | Life-threatening | Common in misuse | Clinical |